^
Association details:
Biomarker:BRCA2 mutation
Cancer:Breast Cancer
Drug:AiRuiYi (fluzoparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

Excerpt:
...Centrally confirmed BRCA1 or BRCA2 germline mutation; 6....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors

Published date:
04/29/2020
Excerpt:
In patients with germline BC susceptibility gene mutation (gBRCA Mut) (11/43 OC; 2/16 BC), mPFS was 8.9 months for OC (range, 1.0-23.2; 95% CI, 1.0-16.8) and 14 and 28 months for BC (those two patients both also had somaticBRCA Mut)….Efficacy in patients with gBRCA1/2Mut gBRCA1/2Mut was tested in 43 patients with OC and 16 patients with BC; 11 in 43 OC (7 gBRCA1Mut, 2 gBRCA2Mut, 2 both gBRCA1/2Mut) and 2 in 16 BC (one gBRCA2Mut, one both gBRCA1/2Mut) had a gBRCAMut.
DOI:
10.21147/j.issn.1000-9604.2020.03.08